TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pain - Visual Analogue Scale (VAS) - Change from 1 hour after pre-treatment baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain - Visual Analogue Scale (VAS) - Change from 1 week after pre-treatment baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants enrolled at 6 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who have completed all baseline and exit questionnaires at 12 weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average intervention participant fitness tracker wear time over 10 weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant satisfaction with the sedentary time intervention at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage change in duodenal polyp burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient-Report Outcome-- Common Terminology Criteria for adverse events (PRO-CTCAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom Severity Scale (SSS)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical assessment of arrested caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in degree of cerebral microbleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage Slowing of Clinical Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in glycated haemoglobin (HbA1c) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in triglycerides (TG) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates and Grades of Cytokine Release Syndrome (CRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience at Least One Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in auditory comprehension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Computer vision syndrome severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amount of bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Days on Therapy (DOT) With Antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability rate of the Mother Daughter Program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total score on an adapted version of the Acceptability of Intervention Measure (AIM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intensity of postoperative pain syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Opioid Usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinically significant change in global Quality of Life (QoL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment response criteria for ABPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in frequency of smartphone use while driving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Free Cortisol (UFC) Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: UFC Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Daily pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Plasma propionate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma butyrate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in hair removal/ hair clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and type of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Bone erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone marrow edema and periarticular soft tissue involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Crystal deposit characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Successful Epicardial Access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ECG characteristics measurement agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COPD assessment test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 30 second sit and stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Time Concentration Curve (AUC 0-35 minutes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Sentinel Lymph Node mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ARMS of SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients for whom ctDNA sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma EBV levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPP-10-C
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Abbreviated Goldberg Anxiety Scale EADG
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gross motor function measure 88
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in MADRS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: miRNA biomarker signatures diagnostic for HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gut microbiome profiling for recurrence prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolome profiling for recurrence prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PIRANI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oximetry monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSEP (Somatosensory Evoked Potentials)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gastric lesion detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients treated with antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: Number of re-admissions
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Beta-hydroxybutyrate (BHB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Erythropoietin (EPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Renin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Threshold vibration stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short term outcomes of ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vascularization score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Effectiveness of intervention (PHQ-9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of intervention (GAD-7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of intervention (PANAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nature of pancreatic lesion (malignant vs benign)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum Total Carotenoid Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Pain in last week
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Higher level of care utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Team Development measure
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Team Compassion Behavior survey
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participation Effort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of healthy volunteers with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to reach peak or maximum observed concentration or response following drug administration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low back pain Oswestry Disability Index Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Delayed MTX clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change from Baseline in Resilience Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change from Baseline in Work Self-Efficacy Score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Change from Baseline in Anxiety Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change from Baseline in Depression Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change from Baseline in Somatic Symptoms Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Methylation Pattern of Genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Me-4FDG PET scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Me-4FDG for lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events of Me-4FDG
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with SARS-CoV-2 S antibody level >5000 U/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: delta quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: General Anxiety Disorder-7 scale (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Assessment of Cancer Therapy-Prostate, Version 4 (FACT-P)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Radiological evaluation of the shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of DLTs observed during the first cycle
Endpoint domain: Adverse events/effects
Primary endpoint: Estimation of PFS rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Time to complete infertility evaluation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to start fertility treatments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Wait time for urology appointments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Wait time for weight management appointments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: clinical course improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sepsis-related glycocalyx injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment as measured by the composite response of 2-grade improvement on Investigator's Live Assessment (ILA) at maximum contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment as measured by the composite response of 2-grade improvement on subject's self-assessment (SSA) at maximum contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in c-ACT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Opioid Consumed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of CAT score responders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of hrHPV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of functional capacities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants with Dose-limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the objective SCORAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Solicited Local Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Any Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of participants achieving 20% improvement in ACR criteria (ACR20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: C-terminal telopeptides of collagen type 1 (CTX) dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EEG memory diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of chronic health conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of chronic health conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of chronic health conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of total iron in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-t of total iron in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of transferrin bound iron in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-t of transferrin bound iron in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Verbal Numerical Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in OHSA composite score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inability to tolerate a solid diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Need for endoscopic or surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for supplemental nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of LBP-EC01 in urine and blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with resolution of clinical symptoms and microbiologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Postpartum Perineal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum Perineal Trauma Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration [Cmax in ng/ml]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration over time (AUC in ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECOG Performance Status Change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dd-cfDNA range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintaining remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative fentanyl requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FCSRT scale score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mitigation of liver inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antitumor Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in six-minute walk distance (Δ6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular energy transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of deep slow-wave sleep (sleep stage N3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Recurrent ECOPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum concentration (Cmax) for SHR-A1811
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) for payload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration curve from time 0 to 16 days (AUC0-16d) for SHR-A1811
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration curve from time 0 to 16 days (AUC0-16d) for payload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local field potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average Time to Achieve Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients with moderate and severe asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional movement screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cue-induced Cravings for Alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caloric and protein adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole Blood Viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in linear growth based on absolute height gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry Disability index (Urdu)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of participants with seroconversion to all poliovirus serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants seropositive to all polio types at 18 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Independent recovery (mRS score of 0-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sitting medicine ball throw test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plate tapping test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kerlan Jobe Orthopedic Clinical Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in forearm muscle glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participation rate in cervical cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Renal volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Infant length for age Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication Composite Index (CCI) at 30 days postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of AEF0117
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of AEF0117
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of AEF0117 (tlast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month radiographic progression-free survival (rPFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Alzheimer's disease (AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurite length measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes